Background First-line pembrolizumab monotherapy improves overall and progression-free
survival in patients with untreated metastatic non-small-cell lung cancer with a programmed …

Background The combination of pembrolizumab and axitinib showed antitumor activity in a
phase 1b trial involving patients with previously untreated advanced renal-cell carcinoma …

Background Most patients with small-cell lung cancer (SCLC) have extensive-stage disease
at presentation, and prognosis remains poor. Recently, immunotherapy has demonstrated …

Background Ipilimumab monotherapy (at a dose of 3 mg per kilogram of body weight), as
compared with glycoprotein 100, improved overall survival in a phase 3 study involving …

Summary Background Palbociclib (PD-0332991) is an oral, small-molecule inhibitor of
cyclin-dependent kinases (CDKs) 4 and 6 with preclinical evidence of growth-inhibitory …

Background The randomized phase II OPUS (Oxaliplatin and Cetuximab in First-Line
Treatment of Metastatic Colorectal Cancer) study showed that tumor KRAS mutation status …

Background We aimed to examine cemiplimab, a programmed cell death 1 inhibitor, in the
first-line treatment of advanced non-small-cell lung cancer with programmed cell death …

Purpose This randomized study assessed whether the best overall response rate (ORR) of
cetuximab combined with oxaliplatin, leucovorin, and fluorouracil (FOLFOX-4) was superior …

Background Combined BRAF and MEK inhibition, as compared with BRAF inhibition alone,
delays the emergence of resistance and reduces toxic effects in patients who have …

Background In the PALOMA-3 study, the combination of the CDK4 and CDK6 inhibitor
palbociclib and fulvestrant was associated with significant improvements in progression-free …